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Summary
Background.— Contrast-induced nephropathy (CIN) severely impacts patient morbidity and
mortality, especially in patients with ST-segment elevation myocardial infarction treated by
primary coronary angioplasty, whose renal function is often unknown at the time of contrast
exposure.
Aim.— We sought the incidence and factors predictive of CIN in patients treated by primary
coronary angioplasty in our hospital; we also questioned the relevance of Mehran’s risk score
in this population.
Methods.— We considered all patients admitted for primary coronary angioplasty between Jan-
uary 2010 and December 2011, and included 322 patients with complete data on renal function.
CIN was deﬁned as a relative (≥ 25%) or absolute (≥ 44mol/L) increase in serum creatinine
following contrast medium administration. We compared patients with or without CIN, to iden-
tify predictive factors, and investigated the effectiveness of Mehran’s score using a receiver
operating characteristic (ROC) curve, Youden’s index and a likelihood ratio test.
Abbreviations: CI, conﬁdence interval; CIN, contrast-induced nephropathy; GFR, glomerular ﬁltration rate; IABP, intra-aortic balloon
ump; MDRD, modiﬁcation of diet in renal disease; STEMI, ST-segment elevation myocardial infarction.
∗ Corresponding author at: Cardiologie A — USCI, CHRU de Tours, 37044 Tours Cedex, France.
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Results.— The incidence of CIN was 9.1%. A multivariable analysis identiﬁed two independent
risk factors for CIN: impaired glomerular ﬁltration rate and cardiogenic shock at admission
(P < 0.05). An elevated Mehran’s score was associated with increased incidence of CIN, but
statistical analysis revealed this score to have poor sensitivity, especially in high-risk patients.
Youden’s index was very low and the area under the ROC curve was 0.59 in our population.
Conclusion.— Renal failure and cardiogenic shock at admission were independent predictors of
CIN in our acute myocardial infarction population. Mehran’s score added little to the discrimi-
nation of patients undergoing primary coronary angioplasty, particularly high-risk individuals.
© 2014 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Produits de
contraste ;
Néphropathie ;
Infarctus du
myocarde ;
Évaluation du niveau
de risque
Résumé
Contexte.— La néphropathie de contraste impacte le pronostic des patients admis pour infarc-
tus du myocarde avec sus-décalage du segment ST traités par angioplastie primaire, pour qui
la fonction rénale est généralement inconnue lors de la prise en charge.
Objectif.— Nous nous sommes intéressés à l’incidence de la néphropathie de contraste chez
les patients admis dans notre centre pour angioplastie primaire et avons cherché à déterminer
l’applicabilité du score de risque de Mehran dans ce contexte.
Méthodes.— Nous avons inclus 322 patients entre janvier 2010 et décembre 2011. La
néphropathie de contraste était déﬁnie comme une élévation relative (≥ 25%) ou absolue
(≥ 44mol/L) de la créatininémie au décours de l’injection de produit de contraste. Nous avons
évalué la pertinence du score de Mehran en comparant patients avec ou sans néphropathie de
contraste en utilisant des rapports de vraisemblance, index de Youden ou courbe ROC.
Résultats.— L’incidence de la néphropathie de contraste était 9,1 %. En analyse multivariée,
seuls l’insufﬁsance rénale préexistante et le choc cardiogénique à l’admission étaient prédic-
tifs de néphropathie de contraste (p < 0,05). Un score de Mehran élevé s’accompagnait d’une
augmentation d’incidence de néphropathie de contraste mais la sensibilité de ce test restait
faible, en faisant un outil peu utile comme en témoignaient les index de Youden bas et l’aire
sous la courbe ROC à 0,59.
Conclusion.— Insufﬁsance rénale et choc cardiogénique apparaissent comme les seuls pré-
dicteurs de néphropathie de contraste chez les patients admis pour infarctus du myocarde.
L’utilité du score de Mehran n’apparaît pas démontrée dans cette population.
© 2014 Elsevier Masson SAS. Tous droits réservés.
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Contrast-induced nephropathy (CIN) refers to potentially
reversible acute renal failure following iodinated con-
trast medium exposure during angiographical procedures or
computed tomography [1,2]. CIN generally occurs within
48 hours of contrast exposure, the increase in serum creati-
nine peaking 5—7days later and usually recovering within
7—10 days [3—5], with the majority of patients returning
to their baseline values. Clinical and metabolic disorders
requiring renal replacement therapy occur in approximately
3% of patients [6,7]. The risk of CIN is even higher in patients
referred for primary coronary angioplasty in the context
of acute coronary syndromes [8—10]. CIN is responsible for
an increased mortality rate of 14% and, for most patients,
correlates with increases in hospital stays and the risk of
cardiovascular complications [11].
Signiﬁcant progress regarding contrast media compo-
sition, notably the decrease in osmolarity [12] and the
constant use of intravenous hydration in high-risk patients,
have resulted in a reduction in the incidence of CIN from
15% to nearly 7% over a decade [13]. However, because of
the increasing number of procedures with iodinated con-
trast media exposure and population aging, resulting in an
w
bncreased prevalence of chronic kidney failure, CIN and its
mpact on morbidity and mortality remains a growing con-
ern.
While it seems that intra-arterial administration of con-
rast medium is associated with a higher risk of CIN than
ntravenous infusion [14—16], primary coronary angioplasty
ppears to be a particularly high-risk procedure, as it affects
population at greater risk of CIN (i.e. older patients with
o-morbidities, such as diabetes, heart failure and chronic
enal failure) [17]. Primary coronary angioplasty has been
hown to be effective in reducing morbimortality in patients
dmitted for acute myocardial infarction, and is the corner
tone of ﬁrst-line therapy in these patients. The main pit-
all is that renal function is often unknown at the time of
ontrast exposure because primary coronary angioplasty has
o be performed without delay, leaving no time for renal
unction assessment. Moreover, the short delay between
atient admission and primary coronary angioplasty signiﬁ-
antly limits the use of pedigree renal protection measures,
uch as intravenous hydration (at least prior to the proce-
ure).Several risk scores have been developed in accordance
ith the main risk factors identiﬁed for CIN, but none has
een adequately validated in the literature [6,13,18—21];
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hus they are currently not recommended for daily practice
y the CIN Consensus Working Panel [22]. Risk scores could,
owever, be of signiﬁcant help in assessing the risk of CIN
n populations where up-to-date data regarding renal func-
ion are missing (e.g. patients undergoing primary coronary
ngioplasty).
The objective of this study was to determine the inci-
ence of CIN in patients treated by primary coronary
ngioplasty for ST-segment elevation myocardial infarction
STEMI) in Tours University Hospital. We also aimed to assess
actors predictive of CIN in this population and the efﬁcacy
f the reference predictive test (Mehran’s score).
ethods
tudy population
e performed a retrospective single-centre study. All
atients undergoing primary coronary angioplasty for STEMI
etween January 2010 and December 2011 in our University
ospital (Tours, France) were considered for inclusion.
STEMI was deﬁned according to the European Society of
ardiology criteria, as: any chest pain lasting > 10minutes
ssociated with a signiﬁcant increase in cardiac biomarkers
nd/or associated with new or presumed new ST-segment
levation of 0.2mV in at least two contiguous leads or
ith the onset of a left bundle branch block [23]. Patients’
ged≥ 18 years who had had primary coronary angioplasty
successful or not) were eligible. Patients were excluded
f they had been exposed to contrast injection within
days before coronary angioplasty or were on chronic renal
eplacement therapy.
tudy protocol
aseline serum creatinine concentration was measured from
blood sample obtained immediately after hospital admis-
ion or at the beginning of primary coronary angioplasty.
he result was usually unavailable at the time of primary
oronary angioplasty. Measurements were usually repeated
t 24, 48 and 72 hours during the patient’s stay in the inten-
ive coronary care unit. All blood samples were processed
y the same laboratory in our hospital (AU2700PlusTM chem-
stry analyser, Beckman Coulter, Brea, CA, USA; and AU640TM
mmunochemistry analyser, Olympus, Center Valley, PA,
SA). Creatinine clearance was calculated using the mod-
ﬁed modiﬁcation of diet in renal disease (MDRD) equation.
According to local custom, most patients received intra-
enous infusion of a 5% glucose solution from initial
anagement by emergency crew to arrival in the catheter-
zation laboratory. No preventive measures for CIN were
ecommended. After coronary angioplasty, infusion of a 5%
lucose solution followed at the usual rate of 1mL/kg/h,
educed to 0.5mL/kg/h in patients with an impaired left
entricular ejection fraction (< 40%), overt heart failure or
ardiogenic shock.
oronary revascularizationollowing our local procedure, primary coronary angioplasty
as performed using either radial or femoral access (at the
iscretion of the operator), with size 6F guide catheters.
atients received a prehospital injection of acetylsalicylic
s
N
d
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cid 250mg in addition to clopidogrel 600mg or pra-
ugrel 60mg when eligible, and an intravenous bolus of
nfractionated heparin (4000—6000 IU, adapted to weight).
ll patients received a monomer non-ionic low-osmolar
ontrast agent (iohexol, OMNIPAQUETM, GE Healthcare
harmaceuticals, Chalfont St. Giles, UK). After identiﬁca-
ion, the culprit lesions were treated by direct coronary
tenting or by balloon predilatation followed by stenting, at
he discretion of the operator. The volume of contrast agent,
he angioplasty technique and the use of pharmaceutical or
echanical haemodynamic support were in accordance with
he European Society of Cardiology guidelines [23].
Cardiogenic shock was deﬁned as acute circulatory
ailure of cardiac origin with a systolic arterial pres-
ure < 80mmHg, refractory to intravenous infusion of 500mL
f saline over 30minutes and resulting in at least two addi-
ional organ failures.
According to our emergency protocol, renal support
haemodialysis or haemoﬁltration) was proposed in cases
f anuria lasting > 24 hours, independent of the patient’s
aemodynamic status.
ndpoints
he main endpoint was the occurrence of CIN, deﬁned
s a relative (≥ 25%) or absolute (≥ 0.5mg/dL; 44mol/L)
ncrease in serum creatinine from baseline within 3 days
fter primary coronary angioplasty. Kidney disease and
hronic renal failure were deﬁned according to the rec-
mmendations of the European Society of Nephrology, as a
lomerular ﬁltration rate (GFR) < 60mL/min/1.73m2, esti-
ated with the modiﬁed MDRD formula [24].
Concomitantly, the risk of CIN was assessed by appli-
ation of Mehran’s score [21], based on the following
ight variables: age (> or < 75 years); hypotension; conges-
ive heart failure; need for haemodynamic support with
ntra-aortic balloon pump (IABP); baseline serum creati-
ine; diabetes; anaemia; and volume of contrast agent.
ehran’s score categorized our population into four differ-
nt groups according to their estimated risk of CIN: a low-risk
roup (score < 5); a medium-risk group (5 < score < 10); a
igh-risk group (10 < score < 15); and a very high-risk group
score > 15).
tatistical analysis
ontinuous data were expressed as mean values± standard
eviations. Categorical data were reported as percent-
ges and absolute values. Comparisons between groups
ere made using the Chi2 test for categorical variables
nd Student’s t-test for continuous variables. A contin-
ous regression model was used to identify variables
ndependently associated with the occurrence of speci-
ed adverse events during follow-up. Potential confounders
ere included in the statistical model to ﬁt. The results
re expressed as relative risks with 95% conﬁdence intervals
CIs). A P value < 0.05 was considered statistically signif-
cant. Statistical analyses were performed with JMP 9.1
oftware (JMP®, SAS® and all others, SAS Institute Inc., Cary,
C, USA). We tested the sensitivity, speciﬁcity, positive pre-
ictive value and negative predictive value of Mehran’s score
or each patient risk group. We used several indicators to
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presented in Table 6.
The area under the ROC curve of the score presented on
Fig. 2 was 0.59.Figure 1. Study design and ﬂowchart. CIN: contrast-induced nep
assess the informative value of the score, including posi-
tive likelihood, negative likelihood, Youden’s index and ROC
curve. Youden’s index, also known as Youden’s J statistic, is
a helpful validated tool to assess the performance of a diag-
nostic test [25,26]; it is easily calculated according to the
formula J = sensitivity + speciﬁcity− 1.
Results
Between January 2010 and December 2011, 427 patients
were admitted for STEMI and underwent primary coronary
angioplasty. Of these, 322 patients with complete data on
renal function at baseline and during the 3-day follow-up
period were included (Fig. 1). Patient characteristics are
presented in Tables 1—3.
Contrast-induced nephropathy and correlates
The incidence of CIN was 9.1% at day 3 in our population.
Univariate analysis (Table 4) identiﬁed several risk fac-
tors for CIN: age > 75 years (P = 0.042), serum creatinine on
admission (P = 0.017), GFR < 60mL/min/1.73m2 (P = 0.014),
occurrence of cardiogenic shock (P = 0.003) and use of
norepinephrine (P = 0.001), dobutamine (P = 0.005) and IABP
(P = 0.001). Of note, neither diabetes (P = 0.234) nor volume
of contrast medium (P = 0.782) was a signiﬁcant risk factor
in our population.
Statistical matching identiﬁed signiﬁcant links between
the variables ‘shock’, ‘norepinephrine’, ‘dobutamine’ and
‘IABP’. To reduce the risk of statistical overweighting in
the multivariable analysis, we only considered the vari-
able ‘shock’, which concerned the largest number of
patients of the four variables, and patients matching
this criterion were not signiﬁcantly different from those
matching the dobutamine, norepinephrine and IABP crite-
ria.
F
Mthy; GFR: glomerular ﬁltration rate.
In the multivariable analysis (Table 5), only GFR <
0mL/min/1.73m2 (P = 0.034) and cardiogenic shock
P = 0.002) were independent predictors of CIN.
elevance of Mehran’s score
e tested the reliability of Mehran’s score in predicting CIN
n our STEMI patients. For each deﬁned group, we deter-
ined the sensitivity, speciﬁcity, positive predictive value,
egative predictive value and Youden’s index. All results areigure 2. Receiver operating characteristic curve (blue line) for
ehran’s score applied to the study population.
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Table 1 Demographic characteristics of the study population and treatment at admission.
Global population
(n = 322; 100%)
CIN (+)
(n = 30; 9.3%)
CIN (−)
(n = 292; 90.7%)
P
Age (years) 63.8± 14.4 63.7± 14.4 63.8± 14.4 0.208
Age > 75 years 77 (23.9) 12 (40.0) 65 (22.3) 0.042
Women 76 (23.6) 8 (26.7) 68 (23.3) 0.7
BMI (g/m2) 27.0± 4.9 27.8± 4.4 26.9± 4.7 0.524
Diabetes 60 (18.6) 8 (26.7) 52 (17.8) 0.234
Type I diabetes 2 (0.3) 0 (0) 2 (0.7) 0.559
Type II diabetes 58 (18.0) 8 (26.7) 50 (17.1) 0.197
Arterial hypertension 163 (50.6) 20 (66.7) 143 (49.0) 0.155
Dyslipidaemia 119 (36.9) 11 (36.7) 108 (37.0) 0.978
Current smoker 131 (40.7) 11 (36.7) 120 (41.1) 0.673
Familial IHD history 38 (11.8) 3 (10.0) 35 (12.0) 0.731
Personal IHD history 38 (11.8) 6 (20.0) 32 (11.0) 0.161
Personal PAD history 21 (6.5) 2 (6.7) 19 (6.6) 0.951
Diuretics 55 (17.1) 7 (23.4) 48 (16.4) 0.349
Thiazide diuretics 29 (9.0) 5 (16.7) 24 (8.2) 0.283
ARBs 53 (16.5) 5 (16.7) 48 (16.4) 0.975
ACE inhibitors 29 (9.0) 5 (16.7) 24 (8.2) 0.391
Statins 82 (25.5) 8 (26.7) 74 (25.3) 0.889
Antiplatelet therapy 60 (18.6) 9 (30.0) 51 (17.5) 0.115
Data are mean± standard deviation or number (%). ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; BMI:
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iscussion
opulation characteristics
he incidence of CIN in our monocentric STEMI popula-
ion undergoing primary coronary angioplasty was 9.1%. This
roportion is similar to the data available in the litera-
ure [11]. Of note, this number was observed despite the
bsence of routine intravenous hydration with 0.9% saline,
s recommended by the CIN Consensus Work Panel. The 3-
ay mortality rate in CIN patients was 10% in our study
3/30), but given the small number of events, it would
e unsafe to compare this result with the data extracted
rom the literature. Because 48% of our patients were
eferred to our centre for primary coronary angioplasty
nd were transferred a few days later to centres close to
heir place of residence, few data are available regarding
onger-term follow-up, particularly the rate of cardiovascu-
ar complications or the need for subsequent dialysis. No
atients required dialysis in the days following coronary
ngioplasty in our population.
The prevalences of several classical risk factors were
ower in our cohort compared with recently published
ata [27]. We observed a higher proportion of patients’
ged≥ 75 years; inversely, the proportion of women was
maller. Diabetes, arterial hypertension, active smoking
a
w
c
eeart disease; PAD: peripheral artery disease.
nd dyslipidaemia were less frequent. Chronic renal failure
GFR < 60mL/min/1.73m2) was more frequently observed in
ur population, but with lower exposition to nephrotoxic
rugs. These differences may jeopardize extrapolation of
ur data to a larger population.
The volume of contrast agent was signiﬁcantly lower than
n most published data (154mL compared with 158mL for
olognese et al., 164mL for Ando et al. and > 216mL for all
thers) [27—31]. The use of haemodynamic support was also
ore limited, despite a higher incidence of haemodynamic
nstability, in line with recent data regarding the efﬁcacy of
ABP [32]. These differences can probably be accounted for
y local habits regarding coronary angioplasty techniques
nd care.
In our population, only two factors identiﬁed by Mehran
ere predictive of CIN. The volume of contrast medium was
ot signiﬁcantly correlated with the occurrence of CIN. Evo-
ution of clinical practice and progress in contrast agent
evelopment may explain this difference. Our cohort ben-
ﬁted from the use of low-osmolarity agents, which are
eemed to be less nephrotoxic. Moreover, the reduced vol-
me of contrast administered was probably lower than the
djusted contrast volume, deﬁned as a threshold above
hich the risk of CIN is signiﬁcantly increased [18]. This
ould explain the incidence of CIN in our population being
quivalent to that in the literature, despite the fact that our
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Table 2 Clinical and biological characteristics of the population; percutaneous coronary intervention data.
Global population
(n = 322; 100%)
CIN (+)
(n = 30; 9.3%)
CIN (−)
(n = 292; 90.7%)
P
Clinical status
Time from onset of chest pain to balloon
(minutes)
301± 227.7 303± 228.3 301.5± 227.2 0.003
Acute left ventricular heart failure 57 (20.1) 6 (20.0) 51 (17.5) 0.332
Acute right ventricular heart failure 10 (4.2) 1 (3.3) 9 (3.1) 0.674
Haemodynamically stable 222 (68.9) 15 (50.0) 210 (71.9) 0.021
Haemodynamic support
Intra-aortic balloon pump 28 (8.7) 7 (23.3) 21 (7.2) 0.001
Dobutamine 26 (8.1) 7 (23.3) 19 (6.5) 0.005
Norepinephrine 19 (5.8) 7 (23.3) 12 (4.1) 0.001
Biological characteristics
Haematocrit (%) 41.9± 4.9 40.3± 4.9 42.1± 5.0 0.145
Haematocrit < 39% 58 (18.0) 8 (26.6) 50 (17.1) 0.144
Plasma proteins (g/L) 68.4± 7.9 68.4± 7.9 68.4± 7.9 0.656
Serum creatinine at day 0 (mol/L) 101.1± 33.6 117.1± 66.9 99.5± 27.7 0.017
GFR (MDRD) at day 0 (mL/min/1.73m2) 70.5± 20.5 64.6± 28.4 71.2± 19.5 0.063
GFR < 60mL/min/1.73m2 91 (28.3) 16 (53.3) 75 (25.7) 0.014
Serum creatinine at day 2 (mol/L) 102.7± 53.1 177.1± 131.5 94.7± 27.5 < 0.0001
Serum creatinine at day 3 (mol/L) 102.9± 46.1 178.1± 111.1 95.7± 25.3 < 0.0001
PCI data
Contrast volume (mL) 154.2± 54.5 154.5± 57.7 154.2± 57.4 0.782
Contrast volume> 100mL 271 (84.1) 26 (86.6) 245 (83.9) 0.72
Contrast volume> 200mL 59 (16.8) 6 (20.0) 53 (18.1) 0.837
Culprit artery
Left main artery 10 (3.1) 1 (3.3) 9 (3.1) 0.925
Left anterior descending artery 147 (45.6) 12 (40.0) 135 (46.2) 0.529
Circumﬂex artery 54 (16.8) 4 (13.3) 50 (17.1) 0.578
Right coronary artery 126 (39.1) 14 (46.7) 112 (38.4) 0.391
Data are mean± standard deviation or number (%). CIN: contrast-induced nephropathy; GFR: glomerular ﬁltration rate; MDRD:
modiﬁcation of diet in renal disease; PCI: percutaneous coronary intervention.
o
t
npatients did not receive systematic intravenous hydration
with saline, as is usually recommended.
In addition, the almost exclusive use of radial access dur-
ing angioplasty procedures may have limited the rate of
atheroembolic renal failure, the difference between this
pathology and CIN being difﬁcult to establish in clinical
practice.
a
i
t
Table 3 Mehran’s score.
Mehran’s score Global population
(n = 322; 100%)
CIN
(n
0 <Mehran’s score < 5 215 (66.7) 11
5 <Mehran’s score < 10 84 (26.0) 9
10 <Mehran’s score < 15 20 (6.2) 7
Mehran’s score > 15 3 (0.9) 3
Data are number (%). CIN: contrast-induced nephropathy.In our population, diabetes did not emerge as a predictor
f CIN. Although the proportion of diabetes here was similar
o that in the French registries of Acute ST-elevation and
on-ST-elevation Myocardial Infarction (FAST-MI) population
nd in line with the epidemiology of diabetes in France,
t was lower than in other CIN studies [33]. There was a
rend for a higher rate of CIN in diabetic patients but the
(+)
= 30; 9.3%)
CIN (−)
(n = 292; 90.7%)
P
(36.6) 204 (69.9) 0.016
(30.0) 75 (25.7) 0.014
(26.6) 13 (4.5) 0.005
(10.0) 0 (0) 0.001
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Table 4 Univariate analysis of contrast-induced nephropathy risk factors.
P OR [CI]
Age > 75 years 0.042 1.7 [1.09—2.89]
Haemodynamic status = shock 0.003 3.6 [1.76—7.40]
Haemodynamic status = stable 0.021 0.7 [0.48—1.01]
Intra-aortic balloon pump 0.001 3.3 [1.53—7.14]
Dobutamine 0.005 3.4 [1.67—8.00]
Norepinephrine 0.001 5.8 [2.47—13.60]
Mean serum creatinine at day 0 0.017 1.01 [1—1.02]
GFR < 60mL/min/1.73m2 at day 0 0.014 3.3 [1.54—7.09]
Average Mehran’s score 0.001 10.3 [0.06—0.24]
0 <Mehran’s score < 5 0.016 0.6 [0.45—0.99]
5 <Mehran’s score < 10 0.014 1.9 [1.22—2.90]
10 <Mehran’s score < 15 0.005 5.4 [1.93—15.04]
Mehran’s score > 15 0.001 NAa
CI: conﬁdence interval; GFR: glomerular ﬁltration rate; NA: not available; OR: odds ratio.
a OR could not be calculated because there were too few patients in this group.
Table 5 Multivariable analysis of contrast-induced nephropathy risk factors.
Univariate analysis Multivariable analysis
P OR [CI] P OR [CI]
Age > 75 years 0.042 1.7 [1.09—2.89] 0.129 4.8 [1.08—2.94]
Cardiogenic shock 0.003 3.6 [1.76—7.40] 0.002 8.8 [2.61—9.74]
GFR < 60mL/min/1.73m2 0.014 3.3 [1.54—7.09] 0.034 10.3 [2.71—15.76]
CI: conﬁdence interval; GFR: glomerular ﬁltration rate; OR: odds ratio.
Table 6 Assessment of the relevance of Mehran’s score for predicting contrast-induced nephropathy in ST-segment
elevation myocardial infarction patients.
Mehran’s score
< 5 6—10 11—15 > 15
Incidence of CIN (%) 6 12 21 75
Sensitivity (%) 41 46 17 10
Speciﬁcity (%) 34 69 95 99
Positive predictive value (%) 6 12 17 75
Negative predictive value (%) 85 93 91 91
Youden’s index −0.24 0.16 0.06 0.09
Positive likelihood ratio 0.62 1.48 3.4 10
Negative likelihood ratio 1.73 0.92 0.87 0.9
CIN: contrast-induced nephropathy.
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small number of patients was certainly the major reason
why this classic risk factor did not emerge from our real-life
study. It is, indeed, widely accepted that diabetic patients
are at higher risk of renal injury when subjected to contrast
agents, because of diabetic kidney disease and concomitant
antidiabetic medication, such as metformin.
There was a trend toward increased risk of CIN in
elderly patients, who generally have several co-morbidities.
Advanced age is often associated with a decline in GFR. This
increased risk probably results from the combination of a
more severe coronary disease with a longer interventional
procedure, an increased rate of heart failure — responsible
for the prescription of intravenous diuretics and reduced
intravenous hydration— and a higher proportion of diabetes
and arterial hypertension, which may cause microvascular
renal lesions.
Among the factors we identiﬁed, impaired renal function
(GFR < 60mL/min/1.73m2) was in line with the literature.
However, in STEMI patients, renal function is barely known
at the time of primary coronary angioplasty, so this factor
cannot play a part in the prediction or prevention of CIN.
Unfortunately, this criterion is therefore irrelevant in most
patients.
The role of cardiogenic shock should be discussed. By
deﬁnition, shock implies potential kidney failure, and in car-
diogenic shock, acute renal failure would correspond to a
type 1 cardiorenal syndrome [34]. This could be a signiﬁcant
confounding factor underestimated by statistical analysis.
As proof, in a subgroup analysis of our population, shock
was also associated with an increased rate of kidney failure
in the population free from CIN (odds ratio 9.7, CI 8.5—48.5;
P < 0.001). Thus, one must remain cautious about the iden-
tiﬁcation of cardiogenic shock as a real predictor of CIN; it
is more a predictor of multifactorial acute renal failure, CIN
being certainly, but not exclusively, part of the process.
Relevance of Mehran’s score
Mehran’s score was one of the CIN risk-scoring schemes that
appeared most relevant to us. However, as with all the
other scores, it has never been validated in prospective
studies and thus is not recommended for daily use by the
CIN Consensus Working Panel. Despite the fact that patients
with STEMI were excluded from the initial population used to
establish this score, we wanted to test its predictive value
in this setting. A few studies have considered the use of
Mehran’s score in STEMI patients for predicting clinical out-
come, but they did not really question the relevance of
this score [31,35]. As our results were similar in terms of
incidence to those in Mehran’s population, we were able to
assess the discriminatory ability of this score.
In the low-risk group, the positive predictive value was
low; this was emphasized by Youden’s index, corresponding
to a score without discriminatory value. This ﬁnding must
be tempered by the low prevalence of CIN in this group (the
largest of our cohort, but relatively less exposed to CIN).
Given the likelihood ratios observed in our population, a CIN
patient was less likely to have a positive test than a non-CIN
patient, which is counterintuitive. In the medium-risk group,
the poor positive predictive value was again notable; this
was conﬁrmed by Youden’s index, emphasizing the low infor-
mative capacity of the score. A new aberration arose from
R431
his group, as a non-CIN patient was less likely to have a neg-
tive test than a patient with conﬁrmed CIN. In the high-risk
roup, the conclusions were the same as those above, due to
poor positive predictive value, with a Youden’s index that
as even poorer, as the sensitivity of the score collapsed to
7%. Similarly, a non-CIN patient was less likely to have a
egative test than a CIN patient. In the very high-risk group,
he very low sensitivity (10%) was not of informative value,
hich penalized Youden’s index. However, the results had
o be weighted by the small number of patients. As in the
edium- and high-risk groups, a non-CIN patient was less
ikely to have a negative test than a CIN patient.
These analyses suggest that Mehran’s test added little to
he discrimination of patients undergoing primary coronary
ngioplasty in our population, regarding the risk of develop-
ng CIN. This was conﬁrmed by the corresponding ROC curve
Fig. 2), where the area under the curve was 0.59.
tudy limitations
his was a retrospective monocentric study with 322
atients, exposed to the usual bias of retrospective analysis.
e found only one prospective study evaluating Mehran’s
core in STEMI patients [31]. This study of selected STEMI
atients showed no difference between CIN odds ratios in
ow-, medium- and high-risk groups deﬁned according to
ehran’s score. Surprisingly, the authors of this work only
mphasized that this score was a good predictor of post
TEMI major adverse cardiac events and did not further dis-
uss the poor prediction of CIN. Our retrospective study,
espite its limitations, provides additional ‘real-life’ data
hat we believe may be of importance for clinicians. As was
ointed out in a recent publication, real-life studies do add
aluable information in clinical research [36]. Our work was
n line with published observational studies and supports the
ctual recommendations of the CIN Consensus Working Panel
egarding the use of risk-scoring schemes in daily clinical
ractice.
onclusions
IN was a conﬁrmed complication of STEMI treated by pri-
ary coronary angioplasty in our population. Our results
uggest that renal failure at admission and cardiogenic
hock are the only independent predictors of CIN, which
ontrasts with previously published data. Mehran’s score
ppeared irrelevant in stratifying the risk of CIN in STEMI
atients, which strengthens the recommendations of the
IN Consensus Working Panel. However, these results and
nterpretations should be subjected to validation in larger
rospective studies.
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